COAG Stock Analysis: Hemab Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.312m USD | 12M Return: 30.5% | US4234941031 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.7M
Warnings
Tailwinds
Seasonality 0.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in the United States and Denmark. Founded in 2020, the company focuses on developing antibody-based therapies for rare blood coagulation disorders, addressing underserved patient populations where few or no prophylactic treatment options currently exist.
The companys lead clinical candidate, HMB-001, is a bispecific antibody being evaluated in Phase 1/2 development for Glanzmann thrombasthenia and Phase 2 development for Factor VII deficiency. A second clinical asset, HMB-002, is a monovalent antibody in Phase 1/2 development for subcutaneous prophylactic treatment of Von Willebrand disease. In addition, Hemab is advancing a pipeline of preclinical and discovery-stage programs.
As a clinical-stage biotech, Hemab has not yet commercialized any products and is therefore dependent on capital markets, partnerships, or future licensing agreements to fund ongoing research and development. The companys strategic emphasis on rare bleeding disorders positions it within the orphan disease segment of the biotechnology sector, where regulatory pathways such as orphan drug designation can offer extended exclusivity and development incentives.
- HMB-001 Phase 1/2 data readout in Glanzmann thrombasthenia
- HMB-002 Phase 1/2 advances in Von Willebrand disease
- Cash burn rate and runway after recent IPO
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 38.19 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.09 > 3% & CFO -44.2m > Net Income -46.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 35.85 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (27.4m) vs prev -37.90% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.96 (Total Current Assets 464.0m - Total Current Liabilities 12.9m) / Total Assets 467.8m |
| B: -0.39 (Retained Earnings -181.9m / Total Assets 467.8m) |
| C: -0.18 (EBIT TTM -49.7m / Avg Total Assets 282.0m) |
| D: 33.62 (Book Value of Equity 454.3m / Total Liabilities 13.5m) |
| Altman-Z'' = 39.18 = AAA |
As of September 04, 2026, the stock is trading at USD 44.37 with a total of 257,208 shares traded. Over the past week, the price has changed by -10.35%, over one month by -1.40%, over three months by +69.55% and over the past year by +30.50%.
Current recommended Stop Loss: 39.50 (which is 11% or 1.2 ATR below the current price).
Hemab Therapeutics has no consensus analysts rating.
P/B = 5.0581
Revenue TTM = 0.0 USD
EBIT TTM = -49.7m USD
EBITDA TTM = -49.5m USD
Long Term Debt = 566k USD (estimated: total debt 1.03m - short term 460k)
Short Term Debt = 460k USD (from shortTermDebt, last quarter)
Debt = 1.03m USD (from shortLongTermDebtTotal, last quarter) (leases 1.06m already included)
Net Debt = -456.4m USD (calculated: Debt 1.03m - CCE 457.5m)
Enterprise Value = 1.86b USD (2.31b + Debt 1.03m - CCE 457.5m)
Interest Coverage Ratio = unknown (Ebit TTM -49.7m / Interest Expense TTM 0.0)
EV/FCF = -41.96x (Enterprise Value 1.86b / FCF TTM -44.2m)
FCF Yield = -2.38% (FCF TTM -44.2m / Enterprise Value 1.86b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.97 (Enterprise Value 1.86b / Total Assets 467.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.03m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -39.3m (EBIT -49.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 35.85 (Total Current Assets 464.0m / Total Current Liabilities 12.9m)
Debt / Equity = 0.00 (Debt 1.03m / totalStockholderEquity, last quarter 454.3m)
Debt / EBITDA = 9.21 (negative EBITDA) (Net Debt -456.4m / EBITDA -49.5m)
Debt / FCF = 10.32 (negative FCF - burning cash) (Net Debt -456.4m / FCF TTM -44.2m)
Total Stockholder Equity = -176.6m (last fiscal year from totalStockholderEquity)
RoA = -16.61% (Net Income -46.8m / Total Assets 467.8m)
RoE = 26.52% (negative equity) (Net Income TTM -46.8m / Total Stockholder Equity -176.6m)
RoCE = 28.22% (negative capital employed) (EBIT -49.7m / Capital Employed (Equity -176.6m + L.T.Debt 566k))
RoIC = -8.62% (negative operating profit) (NOPAT -39.3m / Invested Capital 455.3m)
WACC = 14.10% (E(2.31b)/V(2.31b) * Re(14.11%) + D(1.03m)/V(2.31b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.11% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
[DCF] Fair Price = unknown (Cash Flow -44.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.58 | Chg30d=-10.90% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-3.10 | Chg30d=-1.20% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.54 | Chg30d=-3.71% | Revisions=-25% | GrowthEPS=+18.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -25% (up=0, down=1)